As the key component of Hippo signaling, we therefore suggest that the Yap1/TEAD4/CCNE1/2 could be a potential therapeutic axis in BLCA (Fig. 7), via which metformin can be a potential candidate for the development of novel treatment strategies for human bladder cancer. This evidence concerns the gene YAP1 and urinary bladder carcinoma.